Literature DB >> 27190762

T2 relaxation time is related to liver fibrosis severity.

Alexander R Guimaraes1, Luiz Siqueira1, Ritika Uppal1, Jamu Alford1, Bryan C Fuchs1, Suguru Yamada1, Kenneth Tanabe1, Raymond T Chung1, Gregory Lauwers1, Michael L Chew1, Giles W Boland1, Duhyant V Sahani1, Mark Vangel1, Peter F Hahn1, Peter Caravan1.   

Abstract

BACKGROUND: The grading of liver fibrosis relies on liver biopsy. Imaging techniques, including elastography and relaxometric, techniques have had varying success in diagnosing moderate fibrosis. The goal of this study was to determine if there is a relationship between the T2-relaxation time of hepatic parenchyma and the histologic grade of liver fibrosis in patients with hepatitis C undergoing both routine, liver MRI and liver biopsy, and to validate our methodology with phantoms and in a rat model of liver fibrosis.
METHODS: This study is composed of three parts: (I) 123 patients who underwent both routine, clinical liver MRI and biopsy within a 6-month period, between July 1999 and January 2010 were enrolled in a retrospective study. MR imaging was performed at 1.5 T using dual-echo turbo-spin echo equivalent pulse sequence. T2 relaxation time of liver parenchyma in patients was calculated by mono-exponential fit of a region of interest (ROI) within the right lobe correlating to histopathologic grading (Ishak 0-6) and routine serum liver inflammation [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)]. Statistical comparison was performed using ordinary logistic and ordinal logistic regression and ANOVA comparing T2 to Ishak fibrosis without and using AST and ALT as covariates; (II) a phantom was prepared using serial dilutions of dextran coated magnetic iron oxide nanoparticles. T2 weighed imaging was performed by comparing a dual echo fast spin echo sequence to a Carr-Purcell-Meigboom-Gill (CPMG) multi-echo sequence at 1.5 T. Statistical comparison was performed using a paired t-test; (III) male Wistar rats receiving weekly intraperitoneal injections of phosphate buffer solution (PBS) control (n=4 rats); diethylnitrosamine (DEN) for either 5 (n=5 rats) or 8 weeks (n=4 rats) were MR imaged on a Bruker Pharmascan 4.7 T magnet with a home-built bird-cage coil. T2 was quantified by using a mono-exponential fitting algorithm on multi-slice multi echo T2 weighted data. Statistical comparison was performed using ANOVA.
RESULTS: (I) Histopathologic evaluation of both rat and human livers demonstrated no evidence of steatosis or hemochromatosis There was a monotonic increase in mean T2 value with increasing degree of fibrosis (control 65.4±2.9 ms, n=6 patients); mild (Ishak 1-2) 66.7±1.9 ms (n=30); moderate (Ishak 3-4) 71.6±1.7 ms (n=26); severe (Ishak 5-6) 72.4±1.4 ms (n=61); with relatively low standard error (~2.9 ms). There was a statistically significant difference between degrees of mild (Ishak <4) vs. moderate to severe fibrosis (Ishak >4) (P=0.03) based on logistic regression of T2 and Ishak, which became insignificant (P=0.07) when using inflammatory markers as covariates. Expanding on this model using ordinal logistic regression, there was significance amongst all 4 groups comparing T2 to Ishak (P=0.01), with significance using inflammation as a covariate (P=0.03) and approaching statistical significance amongst all groups by ANOVA (P=0.07); (II) there was a monotonic increase in T2 and statistical significance (ANOVA P<0.0001) between each rat subgroup [phosphate buffer solution (PBS) 25.2±0.8, DEN 5-week (31.1±1.5), and DEN 9-week (49.4±0.4) ms]; (III) the phantoms that had T2 values within the relevant range for the human liver (e.g., 20-100 ms), demonstrated no statistical difference between two point fits on turbo spin echo (TSE) data and multi-echo CPMG data (P=0.9).
CONCLUSIONS: The finding of increased T2 with liver fibrosis may relate to inflammation that may be an alternative or adjunct to other noninvasive MR imaging based approaches for assessing liver fibrosis.

Entities:  

Keywords:  MRI; T2 relaxation time; fibrosis imaging biomarkers; liver fibrosis; quantitative imaging

Year:  2016        PMID: 27190762      PMCID: PMC4858462          DOI: 10.21037/qims.2016.03.02

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  43 in total

1.  Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

Authors:  Laurent Huwart; Christine Sempoux; Eric Vicaut; Najat Salameh; Laurence Annet; Etienne Danse; Frank Peeters; Leon C ter Beek; Jacques Rahier; Ralph Sinkus; Yves Horsmans; Bernard E Van Beers
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

3.  Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis.

Authors:  Christophe Corpechot; Veronique Barbu; Dominique Wendum; Nils Kinnman; Colette Rey; Raoul Poupon; Chantal Housset; Olivier Rosmorduc
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

4.  Nonvascular interventional procedures: analysis of a 10-year database containing more than 21,000 cases.

Authors:  P F Hahn; D A Gervais; M J O'Neill; P R Mueller
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

5.  Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Damien Lucidarme; Juliette Foucher; Brigitte Le Bail; Julien Vergniol; Laurent Castera; Clotilde Duburque; Gérard Forzy; Bernard Filoche; Patrice Couzigou; Victor de Lédinghen
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 6.  Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities.

Authors:  I N Guha; W M Rosenberg
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

7.  Chronic liver disease mortality in the United States, 1990-1998.

Authors:  Sirenda Vong; Beth P Bell
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

Review 8.  Is transient elastography a useful tool for screening liver disease?

Authors:  Paolo Del Poggio; Silvia Colombo
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

9.  Measurement of liver T₁ and T₂ relaxation times in an experimental mouse model of liver fibrosis.

Authors:  April M Chow; Darwin S Gao; Shu Juan Fan; Zhongwei Qiao; Frank Y Lee; Jian Yang; Kwan Man; Ed X Wu
Journal:  J Magn Reson Imaging       Date:  2012-02-14       Impact factor: 4.813

10.  Diagnosis and measurement of liver fibrosis by MRI in bile duct ligated rats.

Authors:  Christophe Aubé; Frédéric Moal; Frédéric Oberti; Jérôme Roux; Vincent Croquet; Yves Gallois; Christophe Argaud; Christine Caron; Paul Calès
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

View more
  20 in total

Review 1.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

2.  MR elastography, T1 and T2 relaxometry of liver: role in noninvasive assessment of liver function and portal hypertension.

Authors:  David H Hoffman; Abimbola Ayoola; Dominik Nickel; Fei Han; Hersh Chandarana; James Babb; Krishna Prasad Shanbhogue
Journal:  Abdom Radiol (NY)       Date:  2020-09

3.  T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis.

Authors:  David H Hoffman; Abimbola Ayoola; Dominik Nickel; Fei Han; Hersh Chandarana; Krishna Prasad Shanbhogue
Journal:  Abdom Radiol (NY)       Date:  2020-03

4.  A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.

Authors:  Zhong-Wei Chen; Huan-Ming Xiao; Xinjian Ye; Kun Liu; Rafael S Rios; Kenneth I Zheng; Yi Jin; Giovanni Targher; Christopher D Byrne; Junping Shi; Zhihan Yan; Xiao-Ling Chi; Ming-Hua Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

5.  Relaxivity-iron calibration in hepatic iron overload: Reproducibility and extension of a Monte Carlo model.

Authors:  Changqing Wang; Scott B Reeder; Diego Hernando
Journal:  NMR Biomed       Date:  2021-08-30       Impact factor: 4.044

6.  Diagnostic performance of quantitative magnetic resonance imaging biomarkers for predicting portal hypertension in children and young adults with autoimmune liver disease.

Authors:  Jonathan R Dillman; Suraj D Serai; Andrew T Trout; Ruchi Singh; Jean A Tkach; Amy E Taylor; Burns C Blaxall; Lin Fei; Alexander G Miethke
Journal:  Pediatr Radiol       Date:  2019-01-03

Review 7.  Putting it all together: established and emerging MRI techniques for detecting and measuring liver fibrosis.

Authors:  Suraj D Serai; Andrew T Trout; Alexander Miethke; Eric Diaz; Stavra A Xanthakos; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2018-08-04

8.  High performance of intravoxel incoherent motion diffusion MRI in detecting viral hepatitis-b induced liver fibrosis.

Authors:  Hua Huang; Nazmi Che-Nordin; Li-Fei Wang; Ben-Heng Xiao; Olivier Chevallier; Yong-Xing Yun; Sheng-Wen Guo; Yì Xiáng J Wáng
Journal:  Ann Transl Med       Date:  2019-02

Review 9.  Basics of magnetic resonance imaging and quantitative parameters T1, T2, T2*, T1rho and diffusion-weighted imaging.

Authors:  Suraj D Serai
Journal:  Pediatr Radiol       Date:  2021-04-15

Review 10.  The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics.

Authors:  Aziz Eftekhari; Allahveirdy Arjmand; Ayyub Asheghvatan; Helena Švajdlenková; Ondrej Šauša; Huseyn Abiyev; Elham Ahmadian; Oleh Smutok; Rovshan Khalilov; Taras Kavetskyy; Magali Cucchiarini
Journal:  Front Chem       Date:  2021-05-14       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.